Related references
Note: Only part of the references are listed.A γ-Secretase Inhibitor Decreases Amyloid-β Production in the Central Nervous System
Randall J. Bateman et al.
ANNALS OF NEUROLOGY (2009)
Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects
Leslie M. Shaw et al.
ANNALS OF NEUROLOGY (2009)
CSF Biomarkers Pinpointing Alzheimer Pathogenesis
Niklas Mattsson et al.
BIOMARKERS IN BRAIN DISEASE (2009)
The Uses of Biomarkers in Drug Development
Orest Hurko
BIOMARKERS IN BRAIN DISEASE (2009)
A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease
Weiming Xia et al.
ARCHIVES OF NEUROLOGY (2009)
Blood-Based Microcirculation Markers in Alzheimer's Disease-Diagnostic Value of Midregional Pro-atrial Natriuretic Peptide/C-terminal Endothelin-1 Precursor Fragment Ratio
Katharina Buerger et al.
BIOLOGICAL PSYCHIATRY (2009)
Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype
Elin S. Blom et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2009)
Future Screening for Incipient Alzheimer's Disease - The Influence of Prevalence on Test Performance
Niklas Mattsson et al.
EUROPEAN NEUROLOGY (2009)
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Niklas Mattsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology
Lidia Glodzik et al.
JOURNAL OF ALZHEIMERS DISEASE (2009)
How can we recognize disease modification effects?
E. R. Siemers
JOURNAL OF NUTRITION HEALTH & AGING (2009)
First Demonstration of Cerebrospinal Fluid and Plasma A beta Lowering with Oral Administration of a beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates
Sethu Sankaranarayanan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008)
L. Lannfelt et al.
LANCET NEUROLOGY (2009)
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
Monica Garcia-Alloza et al.
MOLECULAR NEURODEGENERATION (2009)
Update on amyloid- homeostasis markers for sporadic Alzheimer's disease
Henrik Zetterberg
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2009)
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
Ahmadul Kadir et al.
ANNALS OF NEUROLOGY (2008)
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
Adam S. Fleisher et al.
ARCHIVES OF NEUROLOGY (2008)
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone
Emma L. Akuffo et al.
BIOMARKERS (2008)
Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity:: Prevention by systemic passive immunization
Igor Klyubin et al.
JOURNAL OF NEUROSCIENCE (2008)
PET imaging of amyloid deposition in patients with mild cognitive impairment
Anton Forsberg et al.
NEUROBIOLOGY OF AGING (2008)
Biochemical markers in persons with preclinical familial Alzheimer disease
J. M. Ringman et al.
NEUROLOGY (2008)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease:: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt et al.
LANCET NEUROLOGY (2008)
Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials
Roberto Raschetti et al.
PLOS MEDICINE (2007)
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Sandip Ray et al.
NATURE MEDICINE (2007)
Aspects of β-amyloid as a biomarker for Alzheimer's disease
Ulf Andreasson et al.
BIOMARKERS IN MEDICINE (2007)
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Kaj Blennow et al.
NEUROSCIENCE LETTERS (2007)
Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women
Deborah R. Gustafson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway
Ganesh M. Shankar et al.
JOURNAL OF NEUROSCIENCE (2007)
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years
Henrik Zetterberg et al.
JOURNAL OF ALZHEIMERS DISEASE (2007)
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly
Erik Stomrud et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease
M. Degerman Gunnarsson et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
Carlo Ballatore et al.
NATURE REVIEWS NEUROSCIENCE (2007)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Proteome-based plasma biomarkers for Alzheimer's disease
A. Hye et al.
BRAIN (2006)
Neurochemical aftermath of amateur boxing
Henrik Zetterberg et al.
ARCHIVES OF NEUROLOGY (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan et al.
ANNALS OF NEUROLOGY (2006)
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
ER Siemers et al.
NEUROLOGY (2006)
Anti-A beta(42)- and anti-A beta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model
Y Levites et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The role of biomarkers in clinical trials for Alzheimer disease
LJ Thal et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2006)
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
PJ Visser et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Vitamin E and donepezil for the treatment of mild cognitive impairment
RC Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trials in multiple sclerosis: methodological issues
G Comi et al.
CURRENT OPINION IN NEUROLOGY (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers
E Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2005)
CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
SK Herukka et al.
NEUROLOGY (2005)
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
DG Georganopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897
JJ Anderson et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Studies of Aβ pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque- free) Tg2576 mice using the γ-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide (LY-411575)
TA Lanz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey
M Ganguli et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2004)
Mild cognitive impairment as a diagnostic entity
RC Petersen
JOURNAL OF INTERNAL MEDICINE (2004)
Cerebrospinal fluid markers for prediction of Alzheimer's disease
H Zetterberg et al.
NEUROSCIENCE LETTERS (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition
P Das et al.
NEUROBIOLOGY OF AGING (2001)
Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils
J Götz et al.
SCIENCE (2001)
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
J Lewis et al.
SCIENCE (2001)
Practice parameter: Diagnosis of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
DS Knopman et al.
NEUROLOGY (2001)
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
C Hesse et al.
NEUROSCIENCE LETTERS (2001)
Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma
H Vanderstichele et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2000)
Share Paper
